Design of PD-L1 inhibitors for lung cancer

Area of Science:

• Oncology
• Immunology
• Computational Chemistry

Background:

• Lung cancer progression is linked to the inactivation of programmed cell death protein 1 (PD-1), which suppresses the immune system's T-cell activity.
• PD-1 plays a crucial role in preventing cancer cell growth by regulating immune responses.

Purpose of the Study:

• To identify inhibitors of the PD-L1 dimeric structure using molecular docking and virtual screening.
• To evaluate the potential of a novel compound as a PD-L1 inhibitor.

Main Methods:

• Virtual screening and molecular docking were employed to identify potential inhibitors.
• ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) analysis and cytotoxicity studies were conducted.

Main Results:

• A virtual screened compound (XGIQBUNWFCCMAS-UHFFFAOYSA-N, PubChem CID: 127263272) exhibited high affinity for the PD-L1 target.
• The identified compound demonstrated a superior ADMET profile, including higher intestinal absorption and lower toxicity, compared to the established compound BMS-202.

Conclusions:

• The novel compound XGIQBUNWFCCMAS-UHFFFAOYSA-N is a promising candidate for inhibiting PD-L1.
• This compound presents a potentially safer and more effective therapeutic option for lung cancer treatment.